09:53 AM EDT, 10/15/2024 (MT Newswires) -- SELLAS Life Sciences Group ( SLS ) said Tuesday the US Food and Drug Administration has granted its Galinpeimut-S immunotherapy targeting Wilms Tumor-1 for treating pediatric acute myeloid leukemia Rare Pediatric Disease Designation.

The designation could potentially qualify SELLAS for a "Priority Review Voucher," if the therapy is approved for pediatric AML in the future, the company said.

Shares of the company rose 1.6% in early Tuesday trading.

Price: 1.27, Change: +0.02, Percent Change: +1.60